Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 16/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | FPR1 | P21462 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KDM6B | O15054 | 1/20 | 0.53 |
| ▸ | KDM5C | P41229 | 1/20 | 0.53 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.53 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549478 | 0.69 | KDM5A (1.00) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| Hydrochloric Acid SCHEMBL31236648 | 0.68 | KDM5A (0.98) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL16077821 | 0.64 | KDM5A (0.47) | KDM5AKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL2124113 | 0.63 | KDM5A (0.46) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL6642827 | 0.61 | KDM5A (0.50) | KDM5AKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL2124746 | 0.61 | KDM5A (0.52) | KDM5AGAAKDM6BKDM5CKDM5D | |
| SCHEMBL24309881 | 0.60 | ADORA2A (0.51) | KDM5AKDM4ELMNAHSD17B10 | |
| SCHEMBL826541 | 0.60 | KDM5A (0.58) | KDM5AKDM4EALDH1A1LMNAHSD17B10 | |
| SCHEMBL16966518 | 0.59 | HEXA (0.59) | KDM5ACYP2D6 | |
| SCHEMBL10000551 | 0.58 | TSHR (0.52) | KDM5AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058604-B1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | INSTITUTE FOR CANCER RES (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20220411879-A1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EFFICACY OF EGFR-TARGETED ANTI-CANCER AGENTS | THE GENERAL HOSPITAL CORPORATION | 2022-12-29 | — | — | US | disclosed |
| EP-4058604-A1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2022-04-28 | — | — | US | disclosed |
| CN-114340611-A | Combination of CHIR99021 and valproic acid for the treatment of hearing loss | 频率医疗公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3952854-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | WNT3A, WNT1, MECP2 | KDM5A 291/4885KDM4E 154/4885ALDH1A1 1696/4885 |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | HES1, SHH, HDAC11 | KDM5A 760/4885KDM4E 523/4885ALDH1A1 588/4885 |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT1, WNT3A, CTNNB1 | KDM5A 4354/4885KDM4E 3207/4885ALDH1A1 2821/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | KDM5A 4642/4885KDM4E 4618/4885ALDH1A1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.